|
Jiangsu NHWA Pharmaceutical Co., Ltd (002262.SZ) Valation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) Bundle
Améliorez vos stratégies d'investissement avec la calculatrice DCF (002262SZ)! Utilisez Authentic Jiangsu NHWA Pharmaceutical Co., Ltd Financial Data, ajustez les projections et dépenses de croissance et observez comment ces modifications affectent la valeur intrinsèque de (002262SZ) en temps réel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,149.3 | 3,361.3 | 3,935.7 | 4,298.5 | 4,973.5 | 5,259.7 | 5,562.4 | 5,882.5 | 6,221.0 | 6,579.0 |
| Revenue Growth, % | 0 | -18.99 | 17.09 | 9.22 | 15.7 | 5.75 | 5.75 | 5.75 | 5.75 | 5.75 |
| EBITDA | 876.6 | 948.1 | 1,058.4 | 1,144.7 | 1,339.1 | 1,365.2 | 1,443.8 | 1,526.9 | 1,614.7 | 1,707.6 |
| EBITDA, % | 21.13 | 28.21 | 26.89 | 26.63 | 26.92 | 25.96 | 25.96 | 25.96 | 25.96 | 25.96 |
| Depreciation | 90.0 | 99.3 | 137.8 | 153.8 | 175.1 | 165.4 | 174.9 | 185.0 | 195.6 | 206.9 |
| Depreciation, % | 2.17 | 2.96 | 3.5 | 3.58 | 3.52 | 3.14 | 3.14 | 3.14 | 3.14 | 3.14 |
| EBIT | 786.6 | 848.8 | 920.6 | 991.0 | 1,164.0 | 1,199.8 | 1,268.8 | 1,341.9 | 1,419.1 | 1,500.7 |
| EBIT, % | 18.96 | 25.25 | 23.39 | 23.05 | 23.4 | 22.81 | 22.81 | 22.81 | 22.81 | 22.81 |
| Total Cash | 1,890.8 | 2,239.4 | 2,666.0 | 2,984.2 | 3,493.9 | 3,362.1 | 3,555.6 | 3,760.2 | 3,976.6 | 4,205.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 637.9 | 628.6 | 752.9 | 843.9 | 1,053.5 | 989.0 | 1,046.0 | 1,106.1 | 1,169.8 | 1,237.1 |
| Account Receivables, % | 15.37 | 18.7 | 19.13 | 19.63 | 21.18 | 18.8 | 18.8 | 18.8 | 18.8 | 18.8 |
| Inventories | 345.5 | 433.9 | 604.3 | 716.3 | 628.6 | 693.2 | 733.1 | 775.2 | 819.8 | 867.0 |
| Inventories, % | 8.33 | 12.91 | 15.36 | 16.66 | 12.64 | 13.18 | 13.18 | 13.18 | 13.18 | 13.18 |
| Accounts Payable | 127.5 | 165.2 | 267.2 | 255.7 | 216.3 | 263.8 | 279.0 | 295.0 | 312.0 | 329.9 |
| Accounts Payable, % | 3.07 | 4.91 | 6.79 | 5.95 | 4.35 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 |
| Capital Expenditure | -160.3 | -268.6 | -206.1 | -327.8 | -374.0 | -339.1 | -358.6 | -379.3 | -401.1 | -424.2 |
| Capital Expenditure, % | -3.86 | -7.99 | -5.24 | -7.62 | -7.52 | -6.45 | -6.45 | -6.45 | -6.45 | -6.45 |
| Tax Rate, % | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 |
| EBITAT | 680.2 | 727.4 | 801.9 | 901.7 | 1,032.8 | 1,053.4 | 1,114.0 | 1,178.2 | 1,246.0 | 1,317.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -246.0 | 516.7 | 540.9 | 513.2 | 672.5 | 927.2 | 848.7 | 897.6 | 949.2 | 1,003.8 |
| WACC, % | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 3,960.8 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 1,039 | |||||||||
| Terminal Value | 57,345 | |||||||||
| Present Terminal Value | 44,270 | |||||||||
| Enterprise Value | 48,231 | |||||||||
| Net Debt | -2,068 | |||||||||
| Equity Value | 50,299 | |||||||||
| Diluted Shares Outstanding, MM | 1,007 | |||||||||
| Equity Value Per Share | 49.96 |
What You Will Receive
- Genuine Jiangsu Nhwa Data: Preloaded financial metrics – ranging from revenue to EBIT – based on actual and projected data.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Instant Valuation Adjustments: Automatic recalibrations to assess how changes affect the fair value of Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Adaptable Excel Template: Designed for quick modifications, scenario simulations, and in-depth forecasts.
- Efficient and Reliable: Eliminate the need to construct models from scratch while ensuring accuracy and adaptability.
Key Features
- Advanced DCF Calculator: Offers comprehensive unlevered and levered DCF valuation models tailored for Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable parameters for precise analysis.
- Editable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your projections.
- Built-In Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based NHWA DCF Calculator for Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Input Your Assumptions: Modify the yellow-highlighted cells to set your growth rates, WACC, profit margins, and other key variables.
- Instant Calculations: The model refreshes automatically to reveal the intrinsic value of Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Test Scenarios: Experiment with various assumptions to assess how they impact valuation outcomes.
- Analyze and Decide: Leverage the results to inform your investment choices or financial evaluation.
Why Choose This Calculator for Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ)?
- Precision: Leveraging authentic financial data from Nhwa Pharmaceutical ensures utmost accuracy.
- Customizable: Users can effortlessly test and adjust parameters to meet their needs.
- Efficiency: Eliminate the complexities of constructing a DCF model from the ground up.
- Expert-Level Design: Crafted with the expertise and precision expected at the CFO level.
- Accessible: Intuitive interface makes it suitable for users with varying levels of financial modeling expertise.
Who Should Utilize This Product?
- Individual Investors: Gain valuable insights for making informed decisions regarding investments in Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Financial Analysts: Enhance your valuation processes with accessible financial models tailored for Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Consultants: Provide your clients with accurate and timely valuation insights related to Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
- Business Owners: Learn how large pharmaceutical companies like Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ) are valued to inform your own business strategy.
- Finance Students: Explore valuation techniques using real-world data and scenarios, specifically focusing on Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ).
Overview of the Template's Features
- Pre-Filled DCF Model: Financial data for Jiangsu Nhwa Pharmaceutical Co., LTD (002262SZ) preloaded for instant utilization.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Analyze Jiangsu Nhwa's profitability, leverage, and operational efficiency.
- Editable Inputs: Modify assumptions regarding growth, margins, and CAPEX to suit your specific scenarios.
- Financial Statements: Annual and quarterly reports provided for in-depth analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.